Table 2 Univariate analysis of patient survival according to clinicopathologic characteristics
5-year DFS rate (%) | P | 5-year OS rate (%) | P | |
|---|---|---|---|---|
Gender | 0.313 | 0.601 | ||
Male (n = 79) | 53.4 | 60.7 | ||
Female (n = 57) | 51.7 | 66.7 | ||
Age (years) | 0.643 | 0.475 | ||
<65 (n = 95) | 50.1 | 59.7 | ||
≥65 (n = 41) | 56.8 | 67.2 | ||
Smoking status | 0.541 | 0.312 | ||
Never (n = 103) | 56.5 | 70.6 | ||
Former or current (n = 33) | 46.5 | 54.5 | ||
Tumor size | 0.214 | 0.295 | ||
>3 cm (n = 89) | 46.7 | 59.7 | ||
≤3 cm (n = 43) | 54.2 | 66.2 | ||
Adjuvant chemotherapy | 0.213 | 0.713 | ||
Yes (n = 37) | 59.1 | 67.9 | ||
No (n = 99) | 49.0 | 60.3 | ||
Grade | 0.675 | 0.233 | ||
Well (n = 57) | 59.6 | 73.3 | ||
Moderate or poor (n = 79) | 50.1 | 55.4 | ||
Pleural involvement | 0.769 | 0.961 | ||
Yes (n = 69) | 49.0 | 60.4 | ||
No (n = 67) | 55.2 | 67.5 | ||
Lymphatic and/or vessel invasion | 0.045 | 0.112 | ||
Yes (n = 12) | 39.1 | 51.7 | ||
No (n = 124) | 54.3 | 68.1 | ||
Histological subtypes (IASLC/ATS/ERS) | ||||
Lepidicpredominant | 0.042 | 0.307 | ||
Yes (n = 21) | 75.2 | 80.8 | ||
No (n = 115) | 50.8 | 59.3 | ||
Acinarpredominant | 0.782 | 0.443 | ||
Yes (n = 39) | 55..5 | 67.8 | ||
No (n = 97) | 49.0 | 58.9 | ||
Papillary predominant | 0.401 | 0.405 | ||
Yes (n = 38) | 57.6 | 72.1 | ||
No (n = 98) | 47.1 | 57.2 | ||
Micropapillary predominant | 0.041 | 0.175 | ||
Yes (n = 22) | 28.4 | 43.5 | ||
No (n = 114) | 61.1. | 62.9 | ||
Solid predominant | 0.049 | 0.211 | ||
Yes (n = 14) | 36.7 | 45.9 | ||
No (n = 122) | 57.7 | 65.1 | ||
Variants of invasive adenocarcinoma | 0.315 | 0.306 | ||
Yes (n = 2) | 100 | 100 | ||
No (n = 134) | 51.3 | 60.5 | ||